title: A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|b Tennessee Oncology, PLLC , Nashville , TN , USA.
authors.forename: John D
authors.initials: JD
authors.lastname: Hainsworth
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|b Tennessee Oncology, PLLC , Nashville , TN , USA.
authors.forename: Edward R
authors.initials: ER
authors.lastname: Arrowsmith
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|c Florida Cancer Specialists , Fort Myers , FL , USA.
authors.forename: Michael
authors.initials: M
authors.lastname: McCleod
authors.affiliation: d Cleveland Clinic , Cleveland , OH , USA.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Hsi
authors.affiliation: e Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Oday
authors.initials: O
authors.lastname: Hamid
authors.affiliation: e Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Peipei
authors.initials: P
authors.lastname: Shi
authors.affiliation: e Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Boris K
authors.initials: BK
authors.lastname: Lin
authors.affiliation: f MD Anderson Cancer Center , Houston , TX , USA.
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007211:Indoles; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C504878:enzastaurin; D011241:Prednisone